In contrast, TP53 alterations, including loss of chromosome 17, mutations, and/or deletions in this gene, are frequent in subjects with adverse cytogenetics such as CK-AML and MK-AML [287, 288]. This evidence concerns the gene TP53 and acute myeloid leukemia.